Introduction {#s1}
============

Inflammation, a complex response triggered by pernicious stimuli like pathogens or irritants, verified to be involved in process of many diseases such as Alzheimer Disease, type 2 diabetes, rheumatoid arthritis, etc., (Chiapinotto Spiazzi et al., [@B16]; Garimella et al., [@B32]; Saito et al., [@B96]). Generally, inflammation is classified as acute and chronic type. Acute type only last a few days with neutrophil infiltration, while chronic type can last up to years with infiltrations of lymphocytes and macrophages (Ambrozova et al., [@B3]). Inflammatory pathways perform a crucial part for signal transduction and recent research provide genuine evidence showing NF-κB, MAPK and JAK/STAT are the three main pathways (Bertolini, [@B7]; Ottani et al., [@B88]).

As a famous traditional Chinese medicine (TCM) formula which has been used for centuries, San-Huang-Xie-Xin-Tang (SHXXT) displays good curative activation in the treatment of inflammatory disorders such as atherosclerosis (Wang Y. S. et al., [@B116]), upper respiratory tract infection (Ma et al., [@B80]; Kim et al., [@B51]), diabetic nephropathy (Wu et al., [@B122]), gastritis, gastric bleeding and peptic ulcers (Lo et al., [@B76]), and these protective effects are correlated with reactions of weakening inflammatory by suppressing cytokine/chemokine production. SHXXT has a quite simple composition with only three herbals, namely *Radix et Rhizoma Rhei* (*Rheum palmatum* L.) \[RR, yields anthraquinones like emodin(Emo), rhein(Rhe) and aloe-emodin (Aem)\], *Rhizoma Coptidis* (*Coptis chinensis* Franch) \[RC, yields alkaloids like berberine(Ber) and coptisine(COP)\], *and Radix Scutellaria* (*Scutellaria baicalensis* Georgi) \[RS, yields flavonoids like baicalin(Bai) and baicalein (Bae)\]. Previous studies show the basic effective constituents of SHXXT responsible for the anti-inflammatory effect may be Ber, Bai, Emo, Rhe, and Aem (Ma et al., [@B80]), plus, Bae is considered as a quality control indicator of RS (Zhang et al., [@B141]). In regard of the bioavailability of SHXXT, A rapid and sensitive UPLC-ESI/MS method determined 17 active SHXXT constituents with good linearity in a relatively wide concentration ranges, among which, Bai is the most abundant. In bloodstream, the major forms of SHXXT include Bae, Emo, Aem and Rhe, while only the parent form of Rhe can be detected, and the conjugated effect may be accounted for their physicochemical property differences (Li et al., [@B67]; Shia et al., [@B101]).

Intestinal transporters (IT), such as P-gp, MRP, BCRP (Sampson et al., [@B97]), SGLT1 (Asano et al., [@B4]) and OCT (Bader et al., [@B5]), play a critical role in the process of intracellular and efflux transport. Numerous evidence illustrate the main constituents in SHXXT are the substrates of efflux transporters which leads to a very low oral bioavailability (Huang S. et al., [@B41]; He et al., [@B35]; Wei et al., [@B121]; Di et al., [@B23]). However, most studies only concentrate on solitary constituent, whether they have mutual effect on respective absorption remains to be elucidated.

There\'s growing evidence indicating that all those constituents above, while exclusively dosed, possess anti-inflammation effect by affecting a variety of target molecules in signaling pathways (Shih et al., [@B103]; Hamsa and Kuttan, [@B34]; Zhang et al., [@B140]; Hu et al., [@B37]). We are all clear that, Chinese herbal combination should not only improve curative effects and reduce side effects, but also promote the mutual absorption of effective constituents. In this study, we review the recent studies and discuss how the three classic herbals of SHXXT, RS, RR, and RC, reach the goal of synergistic interaction at both pharmacodynamics and pharmacokinetic level.

Pharmacodynamic level {#s2}
=====================

Effect of the active constituents on molecules in NF-κB pathway
---------------------------------------------------------------

TLR-4 is the first described TLRs in mammals, it responds to LPS which can trigger NF-κB activation and pro-inflammatory cytokines secretion (Lee et al., [@B54]), constituents that can block the binding between TLR-4 and LPS are supposed to be valued in inflammation treatment (Wu et al., [@B123]). As summarized in Table [1](#T1){ref-type="table"}, It is reported that Ber, Bai and Rhe exert inhibitory effect on TLR-4 expression in varies of models (Lee et al., [@B54]; Li et al., [@B60]; Cabrera-Benitez et al., [@B8]; Hou et al., [@B36]; Chen C. C. et al., [@B9]; Chen et al., [@B11]), and the combination of TLR-4 and LPS is observed to be blocked by Ber (Jeong et al., [@B45]). So, it seems that the anti-inflammatory mechanism of SHXXT begins at a really early stage, ever since LPS are interacting with upstream membrane protein.

###### 

**Effect of the active constituents on molecules in NF-κB pathway**.

  **Target**   **Animal or cell culture**       **Model building**     **Control (P or N)**    **Drug**   **Dose**         **Treat time**   **Result**
  ------------ -------------------------------- ---------------------- ----------------------- ---------- ---------------- ---------------- -------------------------------------------------------------------------------
  TLR-4        Microglial cells                 IL-1β                  Vehicle                 Ber        50 μM            24 h             TLR-4 expression↓    Chen C. C. et al., [@B9]
               BALB/c mice                      LPS                    Yohimbine               Ber        50 mg/kg         3 d              TLR-4 mRNA expression in ileum tissue↓    Li et al., [@B60]
               C3H/HeN,C3H/HeJ mice             TNBS                   Vehicle                 Ber        10--20 mg/kg     3 d              TLR-4 expression in colonic epithelial cell↓    Lee et al., [@B54]
               PM cell                          LPS                    Mangiferin              Ber        10,20 μM         1 h              TLR-4 & LPS banding↓    Jeong et al., [@B45]
               Microglial cells                 OGD                    Vehicle                 Bai        40,20.10 ug/ml   24 h             TLR-4 mRNA expression↓    Hou et al., [@B36]
               IgAN SD rats                     BSA, LPS, and CCl~4~   Vehicle                 Rhe        400 mg/kg/d      6 w              TLR-4 expression in renal↓    Chen et al., [@B11]
               BEAS-2B cell                     LPS                    CKT0103                 Rhe        10 μM            18 h             TLR-4 level↓    Cabrera-Benitez et al., [@B8]
               BALB/c mice                      LPS                    TAK-242                 Rhe        100 mg/kg                         TLR-4 expression↓    Zhang et al., [@B138]
               Wistar rats                      LPS                    Vehicle                 Emo        10mg/kg/hr       1,2 h            TLR-4 expression↓    Li A. et al., [@B58]
  MyD88        Microglial cells                 IL-1β                  Vehicle                 Ber        50 μM            24 h             MyD88 expression↓    Chen C. C. et al., [@B9]
               Microglial cells                 OGD                    Vehicle                 Bai        20 ug/ml         2 h              MyD88 activation↓    Hou et al., [@B36]
               C57BL/6 mice                     DSS                    Mesalazine              Bai        100 mg/kg/12 h   7 d              colon MyD88 expression↓    Feng et al., [@B29]
               ICR mice                         Placebo                Ribavirin               Bai        375 mg/kg/d      7 d              MyD88 mRNA expression↓    Wan et al., [@B112]
  TNFR1        HEK293 cell                      TNF-α                  None                    Ber        25 μmol/L        24 h             TNFR1gene expression↓    Pandey et al., [@B89]
  TRADD        HEK293 cell                      TNF-α                  None                    Ber        25 μmol/L        24 h             TRADD gene expression↓    Pandey et al., [@B89]
  TRAF2        HEK293 cell                      TNF-α                  None                    Ber        25 μmol/L        24 h             TRAF2 gene expression↓    Pandey et al., [@B89]
               SAP SD rats                      ST                     SO                      Emo        30 mg/kg         6 h              TRAF2 protein expression↓    Wu et al., [@B124]
  TRAF6        Microglial cells                 OGD                    Vehicle                 Bai        40 ug/ml         4 h              TRAF6 protein level↓    Hou et al., [@B36]
  NIK          HEK293 cell                      TNF-α                  None                    Ber        25 μmol/L        24 h             NIK gene expression↓    Pandey et al., [@B89]
               Fischer 344 rats                 "Age" diet             Young rats              Bai        10,20 mg/kg/d    10 d             NIK phosphorylation↓    Kim et al., [@B52]
  Raf          Fischer 344 rats                 "Age" diet             Young rats              Bai        10,20 mg/kg/d    10d              Raf phosphorylation↓    Kim et al., [@B52]
               U251/U87 cell                    None                   Vehicle                 Ber        15 μM            1-7 d            p-Raf phosphorylation↓    Liu et al., [@B73]
  IRAK1        PM cell                          LPS                    Mangiferin              Ber        10,20 μM         90 min           phosphorylation of IRAK1↓    Jeong et al., [@B45]
  IKK          PM cell                          LPS                    Mangiferin              Ber        10,20 μM         90 min           phosphorylation of IKK-β↓    Jeong et al., [@B45]
               HEK293 cell                      TNF-α                  None                    Ber        25 μmol/L        24 h             IKK-β gene expression↓    Pandey et al., [@B89]
               KM mice                          HCM diet               Vehicle                 Ber        50 mg/kg         2 w              IKKβ phosphorylation in liver and adipose tissue↓    Shang et al., [@B99]
               ARD Wistar rats                  HCM diet               Normal diet             Ber        150 mg/kg/d      12 w             renal IKKβ protein level↓    Wan et al., [@B113]
               Fischer 344 rats                 "Age"diet              Young rats              Bai        10,20 mg/kg/d    10 d             p-IKK expression↓    Kim et al., [@B52]
               HBE16 cells                      LPS                    Vehicle                 Bai        10--100μM        24 h             p-IKK expression↓    Dong et al., [@B26]
               BALB/c mice                      cisplatin              Vehicle                 Bae        50 mg/kg/d       15 d             p-IKK protein expression↓    Sahu et al., [@B95]
               Raw264.7 cell                    LPS                    Vehicle                 Rhe        17.5,35 μM       2 h              IKKβ activity↓    Gao et al., [@B31]
               BALB/c mice                      LPS                    CMCS                    Rhe        20--80 mg/kg/d   7 d              p-IKKβ protein expression↓    Yu et al., [@B131]
  IκBα         PM cell                          LPS                    Yohimbine               Ber        2 μM             90 min           phosphorylation of IκBα↓    Li et al., [@B61]
               Jurkat cell                      TNF-α                  None                    Ber        50 μmol/L        18 h             IκB-α degradation↓    Pandey et al., [@B89]
               Mesangial cell                   LPS                    PDTC                    Ber        30,90 μM         12 h             IκBα protein expression↑    Jiang et al., [@B47]
               BALB/c mice                      DSS                    CK                      Ber        100 mg/kg        3 d              colon IκBα protein expression↑    Li et al., [@B62]
               C57BL/6 mice                     LPS                    Yohimbine               Ber        50 mg/mg         3 d              spleen IκBα phosphorylation↓    Li et al., [@B61]
               BALB/c mice                      DSS                    CK                      Ber        100 mg/kg        3 d              p-IκBα protein expression of in cytoplasm of colon cell↓    Li et al., [@B62]
               Raw264.7 cell                    LPS                    BAY11-7082              Bae        10 μM            2 h              IκBα phosphorylation↓    Fan et al., [@B27]
               BALB/c mice                      Cisplatin              Vehicle                 Bae        50 mg/kg/d       15 d             p-IκBα protein expression↓    Sahu et al., [@B95]
               C57BL/6 mice                     Surgery                SO                      Bae        100 mg/kg/d      7 d              IκBα degradation↓    Wang W. et al., [@B118]
               WKY rats                         LPS                    SO                      Bae        10 mg/kg         6 h              p- IκBα expression↓    Lee et al., [@B56]
               Microglial cells                 OGD                    Vehicle                 Bai        40,20 ug/ml      4 h              p-IκBα protein level↓    Hou et al., [@B36]
               DBA/1 mice                       CII                    PBS                     Emo        10 mg/kg         10 d             IκBα degradation↓    Hwang et al., [@B43]
               HUVECs                           LPS                    DMSO                    Emo        10--50 μg/ml     30 min           IκBα degradation↓    Meng et al., [@B83]
               MEC                              LPS                    Vehicle                 Emo        10,20,40 μg/ml   1 h              IκBα degradation↓    Yang Z. et al., [@B129]
               BMMCs                            PMA+ A23187            PDTC                    Emo        1--20 μM         1 h              p-IκBα / IκBα↓    Lu et al., [@B79]
               Raw264.7 cell                    LPS                    Vehicle                 Rhe        17.5,35 μM       30 min           IκBα phosphorylation↓    Gao et al., [@B31]
               Chondrocytes                     IL-1β                  Vehicle                 Rhe        10 μM            18 h             IκBα degradation↓    Domagala et al., [@B24]
               Raw264.7 cell                    LPS                    BAY11-7082              Aem        10,20 μM         12 h             IκBα degradation↓    Hu et al., [@B37]
               BALB/c mice                      LPS                    CMCS                    Rhe        20--80 mg/kg/d   7 d              p-IκBα protein expression↓    Yu et al., [@B131]
  NF-κB        PM                               LPS                    Yohimbine               Ber        2 μM             90 min           NF-κB translocation and phosphorylation↓    Li et al., [@B61]
               SD rats                          Surgery                Interceed               Ber        0.75,1.5 mg/ml   14 d             NF-κB phosphorylation↓    Zhang et al., [@B144]
               SD diabets rats                  STZ                    Vehicle                 Ber        200 mg/kg        12 w             renal NF-κB expression↓    Xie et al., [@B126]
               Jurkat cell                      TNF-α                  None                    Ber        50 μmol/L        18 h             NF-κB activation↓    Pandey et al., [@B89]
               ARD wistar rats                  HCM diet               Normal diet             Ber        150 mg/kg/d      12 w             Renal NF-κB DNA banding↓    Wan et al., [@B113]
               BALB/cN mice                     Cisplatin              Vehicle                 Ber        3 mg/kg          2 d              NF-κB expression↓    Domitrović et al., [@B25]
               C57BL/6 rats                     Cigarettes             Vehicle                 Ber        50 mg/kg         4d               lung NF-κB DNA banding↓    Lin K. et al., [@B70]
               BALB/c mice                      LPS                    Yohimbine               Ber        50 mg/Kg         3 d              ileum NF-κB activation↓    Li et al., [@B60]
               C3H/HeN, C3H/HeJ rats(colitis)   TNBS                   Vehicle                 Ber        10,20 mg/kg      3 d              colon NF-κB activation↓    Lee et al., [@B54]
               Raw264.7 cell                    LPS                    BAY11-7082              Bae        10 μM            2 h              NF-κB activation↓    Fan et al., [@B27]
               DBA/1 mice                       CII                    PBS                     Emo        10 mg/kg         10 d             NF-κB binding activity↓    Hwang et al., [@B43]
               MEC                              LPS                    Vehicle                 Emo        10,20,40 μg/m    1 h              NF-κB activation↓    Yang Z. et al., [@B129]
               SD rats                          ADM                    Benazepril              Rhe        100 mg/kg/d      6--12 w          Renal NF-κB activation↓    Ji et al., [@B46]
  p65          PM cell                          LPS                    Mesalazine              Ber        10,20 μM         1 h              p65 phosphorylation↓    Jeong et al., [@B45]
               Jurkat cell                      TNF-α                  None                    Ber        50 μmol/L        18 h             p65 phosphorylation and translocation↓    Pandey et al., [@B89]
               NIT-1 cell                       LPS                    Vehicle                 Ber        2.5,5.0 μM       24 h             p65 phosphorylation↓    Hamsa and Kuttan, [@B34]
               Mesangial cell                   LPS                    PDTC                    Ber        30,90 μM         12 h             p65 translocation↓    Jiang et al., [@B47]
               B16F-10 cell                     LPS                    Vehicle                 LPS        2 μg/mL          2 h              p65 DNA-bound↓    Hamsa and Kuttan, [@B34]
               ARD Wistar rats                  HCM diet               Normal diet             Ber        150 mg/kg/d      12 w             Renal p65 protein level↓    Wan et al., [@B113]
               C57BL/6 rats                     Cigarettes             Vehicle                 Ber        50 mg/kg         4 d              p65 translocation↓    Lin K. et al., [@B70]
               BALB/c mice                      DSS                    CK                      Ber        100 mg/kg        3 d              p65 translocation↓    Li et al., [@B62]
               BALB/c mice                      Cisplatin              Vehicle                 Bae        50 mg/kg/d       15 d             p65 translocation↓    Sahu et al., [@B95]
               C57BL/6 mice                     Surgery                SO                      Bae        100 mg/kg/d      7 d              p65 expression↓    Wang W. et al., [@B118]
               C57BL/6 mice                     Ang II                 Vehicle                 Bae        25 mg/kg         14 d             p65 expression↓    Wang A. W. et al., [@B119]
               Raw264.7 cell                    LPS                    BAY11-7082              Bae        10 μM            2 h              p65 translocation↓    Fan et al., [@B27]
               Cardiomyocytes                   I/R                    Vehicle                 Bae        25 μM            30 min           p65 phosphorylation↓    Song et al., [@B104]
               ICR mice                         Placebo                Ribavirin               Bai        375 mg/kg/d      7 d              p65 protein level↓    Wan et al., [@B112]
               WKY rats                         LPS                    SO                      Bae        10 mg/kg         6 h              p-p65 expression↓    Lee et al., [@B56]
               DBA/1 mice                       CII                    PBS                     Emo        10 mg/kg         10 d             p65 translocation↓    Hwang et al., [@B43]
               BALB/c mice                      LPS                    Saline                  Emo        100 mg/kg/12h    3.5 d            p65 phosphorylation↓    Xiao et al., [@B125]
               Wistar rats                      LPS                    Vehicle                 Emo        10 mg/kg/hr      1,2 h            p65 expression↓    Li A. et al., [@B58]
               HUVECs                           LPS                    IL-1β                   Emo        10--50μg/ml      30 min           p65 translocation↓    Meng et al., [@B83]
               MEC                              LPS                    GW9662                  Emo        10,20,40 μg/ml   1 h              p-p65 expression↓    Yang Z. et al., [@B129]
               MDA-MB-435s                      TNF-α                  Vehicle                 Rhe        50--200 μM       48 h             p65 nuclear translocation↓    Fernand et al., [@B30]
               Raw264.7 cell                    LPS                    Vehicle                 Rhe        17.5,35 μM       1 h              p65 level in nuclear↓    Gao et al., [@B31]
               BALB/c mice                      LPS                    CMCS                    Rhe        20--80 mg/kg/d   7 d              p-p65 protein expression↓    Yu et al., [@B131]
  p50          B16F-10 cell                     LPS                    Vehicle                 Ber        2 μg/mL          2 h              p50 DNA-bound↓    Hamsa and Kuttan, [@B34]
               ARD Wistar rats                  HCM diet               Normal diet             Ber        150 mg/kg/d      12 w             renal p50 protein level↓    Wan et al., [@B113]
               DBA/1 mice                       CII                    PBS                     Emo        10 mg/kg         10 d             p50 translocation↓    Hwang et al., [@B43]
               MDA-MB-435s                      TNF-α                  Vehicle                 Rhe        50--200 μM       48 h             p50 nuclear translocation↓    Fernand et al., [@B30]
  GSK3β        HT-29/B6 cell                    TNF-α                  BAY11-7082, Genistein   Ber        50 μM            26,2 h           GSK3β phosphorylation↓    Amasheh et al., [@B2]
  IRF3         PM                               LPS                    Yohimbine               Ber        2 μM             2 h              IRF3 phosphorylation↓    Li et al., [@B61]
               BALB/c mice                      LPS                    Yohimbine               Ber        50 mg/kg         3 d              spleen IRF3 phosphorylation↓    Li et al., [@B61]
               DC1.2 cell                       Poly(I:C)              Vehicle                 Rhe        1--10 μM         5 h              p-IRF3 expression↓    Yuan et al., [@B132]

It has been identified that, MyD88 is recruited by TLR4 at plasma membrane to stimulate the initial activation of IKK, and it may be responsible for the early peak in NF-κB activity (Cheng Z. et al., [@B15]). Apart from MyD88, there are many other adapter molecules (such as TRAF3, TRAM and TRADD) sharing similar activity. NIK will promote NF-κB activation once combined with TRAF2 (Lee et al., [@B55]). Among them, MyD88 has been most systemically studied both *in vivo* and *in vitro*. In respect of these adaptor molecules, Ber and Bai negatively regulate their protein expressions (Pandey et al., [@B89]; Hou et al., [@B36]; Lim et al., [@B69]; Chen C. C. et al., [@B9]; Feng et al., [@B29]; Wan et al., [@B112]), however the main constituents from RR are rarely mentioned.

Enzyme complex IKK (α-γ) have a crucial role in regulating NF-κB signaling pathway (Bagnéris et al., [@B6]). In general, IκBα forms a heterodimer with p65 (RELA) and p50 (NF-κb1), making NF-κB sequestered in cytoplasm. Once activated, IκBα goes phosphorylated meanwhile p65 is liberated and translocate into nuclear, which leads to gene transcription (Pandey et al., [@B89]). Depicted in Figure [1](#F1){ref-type="fig"}, the majority of current studies focus on upstream molecules from IKK to p65. Data in Table [1](#T1){ref-type="table"} show the main constituents of SHXXT can inhibit (1) the expression and phosphorylation of IKK, (2) the expression, phosphorylation and degradation of IκBα, (3) the expression, phosphorylation and translocation of p65 and (4) the expression, phosphorylation, DNA banding and activation of NF-κB in multiple *in-vivo* and *in-vitro* models, such as mesangial (Jiang et al., [@B47]), RAW264.7 (Fan et al., [@B27]), MEC (Yang Z. et al., [@B129]) etc., and ARD rats (Wan et al., [@B113]), C57BL/6 mice (Wang W. et al., [@B118]), DBA/1 mice (Hwang et al., [@B43]), etc.

![**The effect of SHXXT alkaloids on inflammatory pathway molecules**. 1. The green ellipse represents kinase. 2. The purple ellipse represents transcription factor. 3. The red ellipse represents GTpase. 4. The brown ellipse represents phosphatase. 5. The solid arrow represents direct stimulatory modification. 6. The dotted arrow represents translocation. 7. The dotted "T" represents direct inhibitory modification. 8. The red, yellow and blue cross represents the target influenced by RC, RS, and RR constituents, respectively.](fphar-07-00448-g0001){#F1}

We know that, GSK3β is not active until dephosphorylated, and the activation will promote inflammation process undergoes Alzheimer Disease and diabetes (Venna et al., [@B111]). IRF3 is a target of TLR-4 signaling pathway, acting as regulating and activating the transcription of interferon which results inflammatory responses (Cheng B. C. Y. et al., [@B14]). Briefly, phosphorylation of these two downstream molecules are both identified to be reversed by Ber or Rhe treatment in either animal or cell inflammatory model (Amasheh et al., [@B2]; Li et al., [@B61]; Yuan et al., [@B132]), which cover the effect shortage of RS constituents at this part.

Effect of the active constituents on molecules in MAPK pathway
--------------------------------------------------------------

MAPK can be divided into several subfamilies including p38, ERK and JNK (Lou et al., [@B77]). Upstream TAK1 forms a complex consist of TAB1, TAB2, and TRAF6 and then sequentially activate MKK and JNK. The presence of Ras will activate c-raf, MEK and ERK, followed by c-fos regulation once transported into nucleus. Subsequently, the regulated c-fos recruits c-jun to form AP-1 complex (Figure [1](#F1){ref-type="fig"}).

Accumulative data shown in Table [2](#T2){ref-type="table"} leads to a conclusion that p38, ERK, and JNK attract the most focus of study in MAPK pathway. *In-vitro* study results reveal that the increased level of p38, ERK or JNK phosphorylation stimulated by cytokines/chemokines like LPS (Lin Y. et al., [@B71]), IL-1β (Legendre et al., [@B57]), oxLDL (Chen J. et al., [@B10]), PMA (Huang Z. et al., [@B42]), ischemia (Song et al., [@B104]), OGD (Hou et al., [@B36]), HG (Li et al., [@B65]) and CoCl~2~ (Fernand et al., [@B30]), or *in-vivo* elevated level induced by insulin (Lu et al., [@B78]), collagen (Wang Z. et al., [@B120]) and cisplatin (Sahu et al., [@B95]) can be significantly attenuated by either RR, RC, or RS constituent intervention. To further investigate whether p38, ERK and JNK are the only targets, molecules lied on the upstream and downstream are taken into consideration. Turns out, Ber, Bai as well as Rhe treatments all show inhibitory effect on MEK phosphorylation (Shen et al., [@B100]; Lim et al., [@B69]; Liu et al., [@B73]). Nevertheless, for the enhanced phosphorylation of TAK1, Ber is the only reported SHXXT constituent (Zhang et al., [@B144]). In addition, Ber, Bai, or Rhe also display markedly suppressing effect on endonuclear translocation factors like c-fos and CREB (Hamsa and Kuttan, [@B34]), c-jun (Hou et al., [@B36]), ATF-2(Legendre et al., [@B57]), CHOP (Zha et al., [@B137]), or AP-1 complex (Domagala et al., [@B24]).

###### 

**Effect of the active constituents on molecules in MAPK pathway**.

  **Target**   **Animal or cell culture**   **Model building**   **Control (P or N)**   **Drug**   **Dose**         **Treat time**   **Result**
  ------------ ---------------------------- -------------------- ---------------------- ---------- ---------------- ---------------- ------------------------------------------------------
  MEK          Fischer 344 rats             "Age" diet           Young rats             Bai        10,20 mg/kg/d    10 d             MEK phosphorylation↓    Kim et al., [@B52]
               VSMC                         PDGF                 Vehicle                Bai        5--40 μM         48 h             p-MEK phosphorylation↓    Hu et al., [@B39]
               U251/U87 cell                None                 Vehicle                Ber        15 μM            1--7 d           p-MEK phosphorylation↓    Liu et al., [@B73]
               Jurkat cell                  SDF-1β               Pyscion                Emo        1 μg/ml          1 h              p-MEK phosphorylation↓    Shen et al., [@B100]
  TAK1         SD rats                      Surgery              Interceed              Ber        0.75,1.5 mg/ml   14 d             TAK phosphorylation Zhang et al., [@B144]
  JNK          THP-1 cell                   oxLDL                Vehicle                Ber        25 μM            1 h              JNK phosphorylation↓    Chen J. et al., [@B10]
               RAW264.7 cell, PM            LPS                  Vehicle                Ber        5 μM             2 h              JNK phosphorylation↓    Jeong et al., [@B44]
               PM                           LPS                  Yohimbine              Ber        2 μM             90 min           JNK activation↓    Li et al., [@B61]
               CIA SD rats                  Collagen             PBS                    Ber        200 mg/kg        28 d             JNK expression↓    Wang Z. et al., [@B120]
               SD rats                      Surgery              Interceed              Ber        0.75,1.5 mg/ml   14 d             JNK phosphorylation↓    Zhang et al., [@B144]
               BALB/c mice                  LPS                  Yohimbine              Ber        50 mg/kg         3 d              Spleen JNK phosphorylation↓    Li et al., [@B61]
               CIA SD rats                  Collagen             PBS                    Ber        200 mg/kg        28 d             p-JNK expression↓    Wang Z. et al., [@B120]
               NIT-1 cell                   LPS                  Vehicle                Ber        2.5,5.0 μM       24 h             p-JNK expression↓    Hamsa and Kuttan, [@B34]
               Cardiomyocytes               I/R                  Vehicle                Bae        25 μM            30 min           JNK1/2 phosphorylation↓    Song et al., [@B104]
               Microglial cells             OGD                  Vehicle                Bai        40,20 ug/ml      4 h              p-JNK protein level↓    Hou et al., [@B36]
               BALB/c mice                  Cisplatin            Vehicle                Bae        50 mg/kg/d       15 d             p-JNK expression↓    Sahu et al., [@B95]
               C57BL/6 mice                 Surgery              SO                     Bae        100 mg/kg/d      7 d              p-JNK expression↓    Wang W. et al., [@B118]
               TRMs rats                    None                 WT                     Bae        10--40 mg/kg     14 d             p-JNK expression↓    Mao et al., [@B82]
               SAP SD rats                  ST                   SO                     Emo        30 mg/kg         6 h              p-JNK protein expression↓    Wu et al., [@B124]
               BMMCs                        PMA+ A23187          SP600125               Emo        1--20 μM         1 h              p-JNK/JNK↓    Lu et al., [@B79]
               MEC                          LPS                  Vehicle                Emo        10,20,40 μg/ml   1 h              p-JNK expression↓    Yang Z. et al., [@B129]
               Chondrocytes                 IL-1β                DMSO                   Rhe        100 μM           18 h             JNK activation↓    Legendre et al., [@B57]
               Raw264.7 cell                LPS                  SP600125               Aem        5,10,20 μM       4 h              JNK phosphorylation↓    Hu et al., [@B37]
  ERK          PM                           LPS                  Yohimbine              Ber        2 μM             90 min           ERK activation↓    Li et al., [@B61]
               HepG2 cell                   Palmitate            PD98059                Ber        10 μM            30 min           ERK phosphorylation↓    Lu et al., [@B78]
               BV2 microglial               IFN-γ                Vehicle                Ber        10 μM            30 min           ERK phosphorylation↓    Lu et al., [@B78]
               RAW264.7 cell, PM            LPS                  Vehicle                Ber        5 μM             2 h              ERK phosphorylation↓    Jeong et al., [@B44]
               BALB/c mice                  LPS                  Yohimbine              Ber        50 mg/kg         3 d              Spleen ERK phosphorylation↓    Li et al., [@B61]
               CIA SD rats                  Collagen             PBS                    Ber        200 mg/kg        28 d             p-ERK expression↓    Wang Z. et al., [@B120]
               U266 cells                   IL-6                 PD98059                Bae        50 μM            1 h              ERK1/2 phosphorylation↓    Liu et al., [@B74]
               Fischer 344 rats             "Age" diet           Young rats             Bai        10,20 mg/kg/d    10 d             p-ERK1/2 expression↓    Kim et al., [@B52]
               BALB/c mice                  Cisplatin            Vehicle                Bae        50 mg/kg/d       15 d             p-ERK expression↓    Sahu et al., [@B95]
               C57BL/6 mice                 Surgery              SO                     Bae        100 mg/kg/d      7 d              p-ERK expression↓    Wang W. et al., [@B118]
               C57BL/6 mice                 Ang II               Vehicle                Bae        25 mg/kg         14 d             p-ERK1/2 expression↓    Wang A. W. et al., [@B119]
               Chondrocytes                 IL-1β                Vehicle                Rhe        10 μM            18 h             ERK1/2 phosphorylation↓    Domagala et al., [@B24]
               Chondrocytes                 IL-1β                DMSO                   Rhe        100 μM           18 h             ERK activation↓    Legendre et al., [@B57]
               BALB/c mice                  LPS                  Vehicle                Emo        1--4 mg/kg       12 h             ERK phosphorylation↓    Li D. et al., [@B59]
               MEC                          LPS                  Vehicle                Emo        10,20,40 μg/ml   1 h              p- ERK expression↓    Yang Z. et al., [@B129]
               BMMCs                        PMA+ A23187          U0126                  Emo        1--20 μM         1 h              p- ERK / ERK ↓    Lu et al., [@B79]
               Raw264.7 cell                LPS                  PD98059                Aem        5,10,20 μM       12 h             ERK1/2 phosphorylation↓    Hu et al., [@B37]
  P38          THP-1                        oxLDL                Vehicle                Ber        25 μM            1 h              p38 phosphorylation↓    Chen J. et al., [@B10]
               THP-1                        PMA                  Vehicle                Ber        5--50 μM         1 h              Block p38 pathway Huang Z. et al., [@B42]
               RAW264.7 cell, PM            LPS                  Vehicle                Ber        5 μM             2 h              p38 phosphorylation↓    Jeong et al., [@B44]
               CIA SD rats                  Collagen             PBS                    Ber        200 mg/kg        28 d             p-p38 expression↓    Wang Z. et al., [@B120]
               SD rats                      LPS                  Vehicle                Ber        100 mg/kg        24 h             p38 expression↓    Godugu et al., [@B33]
               BALB/cN mice                 Cisplatin            Vehicle                Ber        3 mg/kg          2 d              Renal p38 expression↓    Domitrović et al., [@B25]
               Cardiomyocytes               I/R                  Vehicle                Bae        25 μM            30 min           p38 phosphorylation↓    Song et al., [@B104]
               Microglial cells             OGD                  Vehicle                Bai        40, 20 ug/ml     4 h              p-p38 protein level↓    Hou et al., [@B36]
               BALB/c mice                  Cisplatin            Vehicle                Bae        50 mg/kg/d       15 d             p-p38 expression↓    Sahu et al., [@B95]
               C57BL/6 mice                 Surgery              SO                     Bae        100 mg/kg/d      7 d              p-p38 expression↓    Wang W. et al., [@B118]
               TRMs rats                    None                 WT                     Bae        10--40 mg/kg     14 d             p-p38 expression↓    Mao et al., [@B82]
               HUVECs                       LPS                  Vehicle                Rhe        0,5,10,20 μM     24 h             p38 phosphorylation↓    Hu et al., [@B38]
               HUVECs                       LPS                  ip38                   Rhe        20 μM            24 h             p38 phosphorylation↓    Lin Y. et al., [@B71]
               SAP SD rats                  ST                   SO                     Emo        30 mg/kg         6 h              p-p38 protein expression↓    Wu et al., [@B124]
               HBZY-1                       HG                   SB203580               Emo        30--60 μM        24 h             p-p38 protein expression↓    Li et al., [@B65]
               MEC                          LPS                  Vehicle                Emo        10,20,40 μg/ml   1 h              p-p38 protein expression↓    Yang Z. et al., [@B129]
               BMMCs                        PMA+ A23187          SB203580               Emo        1--20 μM         1 h              p-p38 /p38↓    Lu et al., [@B79]
               HUVECs                       CoCl~2~              Vehicle                Rhe        50 μM            6 h              p-ERK acivation↓    Fernand et al., [@B30]
               Raw264.7 cell                LPS                  SB203580               Aem        10,20 μM         4 h              p38 phosphorylation↓    Hu et al., [@B37]
  IRS-1        3T3-L1 cell                  TNF-α                Pioglitazone           WE         30--100 mg/L     24 h             IRS-1 phosphorylation↓    Yuan et al., [@B133]
               HepG2 cell                   Palmitate            SS                     Ber        0.1--10 μM       30 min           IRS-1 phosphorylation↓    Lou et al., [@B77]
  MAPK APK2    HUVECs                       LPS                  ip38                   Rhe        20 μM            24 h             MAPKAPK2 phosphorylation↓    Lin Y. et al., [@B71]
  CREB         B16F-10 cell                 LPS                  Vehicle                Ber        2 μg/ml          2 h              CREB DNA-bound↓    Hamsa and Kuttan, [@B34]
  c-Rel        B16F-10 cell                 LPS                  Vehicle                Ber        2 μg/ml          2 h              c-Rel DNA-bound↓    Hamsa and Kuttan, [@B34]
  c-fos        B16F-10 cell                 LPS                  Vehicle                Ber        2 μg/ml          2 h              c-Fos DNA-bound↓    Hamsa and Kuttan, [@B34]
  c-jun        Microglial cells             OGD                  Vehicle                Bai        40 ug/ml         4 h              p-c-jun protein level↓    Hou et al., [@B36]
  AP-1         Chondrocytes                 IL-1β                DMSO                   Rhe        100 μM           18 h             AP-1 DNA binding↓    Legendre et al., [@B57]
               Chondrocytes                 IL-1β                Vehicle                Rhe        10 μM            18 h             AP-1 DNA binding↓    Domagala et al., [@B24]
               ICR mice                     Placebo              Ribavirin              Bai        375 mg/kg/d      7 d              c-jun/AP-1 expression↓    Wan et al., [@B112]
  ATF2         B16F-10 cell                 LPS                  Vehicle                Ber        2 μg/ml          2 h              ATF-2 DNA-bound↓    Hamsa and Kuttan, [@B34]
  CHOP         J744A.1 macrophages          Protease inhibitor   Vehicle                Ber        0--2.0 mg/ml     2 h              nuclear CHOP expression↓    Zha et al., [@B137]

Effect of the active constituents on molecules in AMPK pathway
--------------------------------------------------------------

AMPK serves as a cellular energy sensor to modulate lipid metabolism, and it can be activated by upstream kinases like LKB1 and CaMKK (Yang Y. et al., [@B128]; Li N. S. et al., [@B63]). There is a mechanism underlined the relationship, thus once AMPK activated, the nuclear translocation of Nrf2 is promoted, which contribute to the diminution of pro-inflammatory cytokines production. Nrf2 can also drive downstream HO-1 expression in with the considerable beneficial protect effect against cell injury from inflammatory response like diabetes mellitus (Agca et al., [@B1]). PPAR-γ is identified as a primary regulator of gene expression for inflammation and a pharmacological receptor of insulin-sensitizing drugs (Choi et al., [@B19]).

As summed up in Table [3](#T3){ref-type="table"}, the current study status demonstrate that Ber from RC exert the most comprehensive effect compared with other constituents form RR and RS, pathway molecules from upstream to downstream, including CaMKII, LKB1, PPAR-γ (Legendre et al., [@B57]), AMPK (Lu et al., [@B78]), Nrf2 and HO-1(Mo et al., [@B84]) are all verified to be the effective targets of Ber. In addition, Emo (Yang Z. et al., [@B129]; Wang T. et al., [@B117]), Bai and Bae (Lim et al., [@B69]; Ma et al., [@B81]; Feng et al., [@B28]; Tsai et al., [@B110]) as well affect some of those molecules. Given this investigation situation, it seems that constituents from either RR, RS, or RC can block AMPK pathway by cross-talk regulating pathway molecules.

###### 

**Effect of the active constituents on molecules in AMPK pathway**.

  **Target**   **Animal or cell culture**   **Model building**   **Control (P or N)**   **Drug**   **Dose**    **Treat time**   **Result**
  ------------ ---------------------------- -------------------- ---------------------- ---------- ----------- ---------------- ---------------------------------------------------------
  CaMK-II      BV2 microglial cell          LPS or IFN-γ         Vehicle                Ber        10 μM       2 h              CaMKII ~(Thr286)~ phosphorylation↑    Lu et al., [@B78]
  LKB1         BV2 microglial cell          LPS or IFN-γ         Vehicle                Ber        10 μM       2 h              LKB1 phosphorylation↑    Lu et al., [@B78]
  AMPK         BV2 microglial cell          LPS or IFN-γ         Vehicle                Ber        10 μM       2 h              AMPK ~(*Thr*172)~ phosphorylation↑    Lu et al., [@B78]
               Hela cell                    None                 Compound C             Bai        1 μM        3 h              AMPK phosphorylation↑    Ma et al., [@B81]
  HO-1         PM                           LPS                  Vector                 Ber        10 μM       24 h             HO-1 mRNA expression↑    Mo et al., [@B84]
               SD rats                      LPS                  Vehicle                Bae        20 mg/kg    7 h              HO-1 protein expression↑    Tsai et al., [@B110]
               BALB/c mice                  Dox                  Vehicle                Bae        25 mg/kg    24 d             HO-1 protein expression↑    Sahu et al., [@B94]
               C57BL/6 mice                 OVA                  Dex                    Emo        10 mg/kg    3 d              HO-1 mRNA expression↑    Wang T. et al., [@B117]
  Nrf2         PM                           LPS                  Vector                 Ber        10 μM       24 h             Nrf2 translocation↑    Mo et al., [@B84]
               SD rats                      LPS                  Vehicle                Bae        20 mg/kg    7 h              Nrf2 nuclear translocation↑    Tsai et al., [@B110]
               BALB/c mice                  Dox                  Vehicle                Bae        25 mg/kg    24 d             Nrf2 protein expression↑    Sahu et al., [@B94]
  PPAR -γ      3T3-L1 cell                  TNF-a                Pioglitazone           WE         30 mg/L     24 h             PPAR-γ mRNA expression↑Yuan et al., [@B133]
               SD rats                      LPS                  SR-202                 Bai        25 mg/kg    3 d              intestinal PPAR-γ level↓    Feng et al., [@B28]
               Fischer 344 rats             Aged                 TZD;GW9662             Bai        10 mg/kg    3 d              PPAR-γ protein expression↓    Lim et al., [@B69]
               HBZY-1                       HG                   SB203580               Emo        30--60 μM   24 h             PPAR-γ protein expression↑    Li et al., [@B65]
               MEC                          LPS                  Rosiglitazone          Emo        10 μg/ml    1 h              PPAR-γ activation↑    Yang Z. et al., [@B129]

Effect of the active constituents on molecules in JAK/STAT pathway
------------------------------------------------------------------

The activation of JAK catalyze Tyr phosphorylation so that STAT can be combined with receptor protein, then transported into nucleus to regulate transcription. It has been reported that STAT1 and STAT5, the downstream molecules of IFN-γ, are also likely to be implicated in inflammation (Chmielewski et al., [@B17]; Li X. et al., [@B66]). Akt functions as emerging crucial regulator of multiple cellular processes, such as apoptosis, differentiation, survival, etc., (Piao et al., [@B92]). Moreover, recent studies indicate PI3K/Akt can lead to an elevated expression level of COX-2 and iNOs in inflammatory macrophages (Liou et al., [@B72]). Further activated mTOR can regulate cell growth, differentiation as well as transcription and it tends to perform abnormally in diabetes models (Hua and Hu, [@B40]).

For JAK/STAT pathway, constituents from RC, RS and RR are all showing inhibitory activity, typical targets include JAK (Kim et al., [@B50]; Qi et al., [@B93]; Subramaniam et al., [@B106]), STAT (Cui et al., [@B22]; Liu et al., [@B74]; Kim et al., [@B53]) and Akt (Lou et al., [@B77]; Hu et al., [@B37]; Wang A. W. et al., [@B119]), all of which are proved to be influenced by Ber, Bae, Bae, Emo or Aem in either *in-vivo* or *in-vitro* models (Table [4](#T4){ref-type="table"}). On the other hand, results in the study concerning about downstream molecular present main RR constituent\'s effect-weakness on targets like Tyk2. Apparently, RS and RC cover the shortfalls of RR\'s poor activity in downstream pathway, which partly supports the synergistic theory of drug combination aiming at promoting curative effect.

###### 

**Effect of the active constituents on molecules in JAK/STAT pathway**.

  **Target**   **Animal or cell culture**   **Model building**   **Control (P or N)**     **Drug**   **Dose**             **Treat time**   **Result**
  ------------ ---------------------------- -------------------- ------------------------ ---------- -------------------- ---------------- ------------------------------------------------------
  JAK1         Raw264.7 cell                LPS                  Vehicle                  Bae        20--80 μM            2 h              JAK1 phosphorylation↓    Qi et al., [@B93]
               NOP2 cells                   IL-6                 None                     Bae        50 μM                1 h              JAK1 phosphorylation↓    Liu et al., [@B74]
  JAK2         Raw264.7 cell                LPS                  Vehicle                  Bae        20--80 μM            2 h              JAK2 phosphorylation↓    Qi et al., [@B93]
               HepG2                        None                 Vehicle                  Emo        50 μM                12 h             JAK2 phosphorylation↓    Subramaniam et al., [@B106]
  JAK3         Nb2 cell                     IL-2                 Vehicle                  Ber        1--10 μM             1 h              JAK3 phosphorylation↓    Kim et al., [@B50]
  STAT1        NOD rats CD4+ T cell         None                 Vehicle                  Ber        200 mg/kg 5, 10 μM   2 w              STAT1 phosphorylation↓    Cui et al., [@B22]
               BALB/c mice                  LPS                  Yohimbine                Ber        50 mg/kg             3 d              Spleen STAT1 phosphorylation↓    Li et al., [@B61]
               U266 cells                   IL-6                 None                     Bae        12.5--50 μM          1 h              STAT1 phosphorylation↓    Liu et al., [@B74]
  STAT3        NOD rats CD4+ T cell         None                 Vehicle                  Ber        200 mg/kg 5, 10 μM   2 w              STAT3 phosphorylation↓    Cui et al., [@B22]
               U266cells                    IL-6                 None                     Bae        50,100 μM            1 h              STAT3 phosphorylation↓    Liu et al., [@B74]
               GSCs                         None                 Vehicle                  Emo        5 μM                 24 h             p-STAT3 phosphorylation↓    Kim et al., [@B53]
               RPMI8266                     IL-6                 Dox                      Emo        50 μmol/L            12 h             STAT3 phosphorylation↓    Muto et al., [@B86]
  STAT5        Nb2 cell                     IL-2                 Vehicle                  Ber        1,3,7,10 μM          1 h              STAT5 phosphorylation↓    Kim et al., [@B50]
  STAT4        NOD rats CD4+ T cell         None                 Vehicle                  Ber        200 mg/kg 5, 10μM    2 w              STAT4 phosphorylation↓    Cui et al., [@B22]
               Arthritis mice               kaolin               Prednisolone             Ber        10--50 mg/kg         6 d              synovial expression STAT4↓    Kim et al., [@B50]
  STAT6        Arthritis mice               kaolin               Prednisolone             Ber        10--50 mg/kg         6 d              synovial expression STAT6↓    Kim et al., [@B50]
  Tyk2         BALB/c mice                  LPS                  Yohimbine                Ber        50 mg/kg             3 d              Spleen Tyk2 phosphorylation↓    Li et al., [@B61]
               NOP2 cells                   IL-6                 None                     Bae        25 μM                1 h              Tyk2 phosphorylation↓    Liu et al., [@B74]
  Src-P        HT-29/B6 cell                TNF-α                BAY11-7082, Genistein    Ber        50 μM                26 h             Src-P phosphorylation↓    Amasheh et al., [@B2]
  Akt          HT-29/B6 cell                TNF-α                BAY11-7082, Genistein    Ber        50 μM                26 h             Akt phosphorylation↓    Amasheh et al., [@B2]
               HepG2 cell                   Paimitate            PD98059,SS, BAY11-7082   Ber        0.1--10 μM           30 min           Akt phosphorylation↓    Lou et al., [@B77]
               NOP2 cells                   IGF-1                None                     Bae        10 μM                30 min           Akt phosphorylation↓    Liu et al., [@B74]
               HUVECs                       CoCl~2~              Vehicle                  Rhe        50 μM                6 h              p-Akt activation↓    Fernand et al., [@B30]
               Raw264.7 cell                LPS                  LY294002                 Aem        10,20 μM             4 h              Akt phosphorylation↓    Hu et al., [@B37]
               C57BL/6 mice                 Ang II               Vehicle                  Bae        25 mg/kg             14 d             p-Akt expression↓    Wang A. W. et al., [@B119]
               SD rats                      Adjuvant             Ibuprofen                Rhe        50 mg/kg             21 d             p-Akt/Akt level↓    Cong et al., [@B20]
  PI3K         HUVECs                       CoCl~2~              Vehicle                  Rhe        50 μM                6 h              PI3K activation↓    Fernand et al., [@B30]
               HT-29/B6 cell                TNF-α                BAY11-7082, Genistein    Ber        50 μM                26 h             PI3K activation↓    Amasheh et al., [@B2]
  mTOR         CRC cells                    None                 Vehicle                  Ber        15--60 μM            24 h             mTOR phosphorylation↓    Li W. et al., [@B64]
               C57BL/6 mice                 Ang II               Vehicle                  Bae        25 mg/kg             14 d             p-mTOR expression↓    Wang A. W. et al., [@B119]

Pharmacokinetic level {#s3}
=====================

Traditional Chinese medicines are frequently orally administrated and the absorption of active constituents are confirmed to be influenced by efflux pumps and intestinal transporters (ITs) (Park et al., [@B90]; Zumdick et al., [@B147]). In general, ITs widely distribute in intestinal membrane and can be divided into two categories. One accounts for external substance\'s intracellular transport, such as OCTs and SGLT1 (Moran et al., [@B85]; Couroussé and Gautron, [@B21]). The other one, like P-gp, MRP and BCRP, is functioning as efflux pump to make drug or toxin back to lumen (Yamagata et al., [@B127]; Juan et al., [@B48]; Zeng et al., [@B134]). There are many isolate reports showing SHXXT\'s main constituents have an unexpectedly low concentration in plasma with oral administration, making it challenged to explain its positive effects in inflammatory therapies.

*In-vitro* research on the efflux pump and ITs normally use Caco-2 cell or MDCK cell for they both have similar structure of differential intestinal epithelial cell with apical side and basolateral side (Chen et al., [@B13]; Schexnayder and Stratford, [@B98]; Obringer et al., [@B87]). Currently, it is verified that Bai from RS is the substrate of both MRP2 and BCRP (Kalapos-Kovács et al., [@B49]), and another RS constituent Bae is also pumped out by MRP (Zhang et al., [@B139]). Rhe, Emo and Aem from RR are substrate of BCRP, MRP and P-gp respectively (Wang J. et al., [@B115]; Liu et al., [@B75]; Ye et al., [@B130]), those ITs at least partly reduce the bioavailability of SHXXT constituents by diminishing their intracellular transport. Similarly, the absorption of Ber, Pal, Cop and Jat form RC is reported to be promoted by OCTs while inhibited by P-gp (Chen et al., [@B12]; Zhang et al., [@B143]; Sun et al., [@B108]). In addition to OCTs, SGLT1 also contributes to uptake (Zhang et al., [@B145]). Thus, any constituents in SHXXT which suppress the MRP2, BCRP, and P-gp activation or, on the other hand, up-regulate OCTs and SGLT1 activation may be considered to exert mutual reinforcement property by promoting bioavailability.

In return, constituents in SHXXT show retroaction on those efflux pump or ITs. Depicted in Figure [2](#F2){ref-type="fig"}, Firstly, P-gp, which reduces the absorption of Ber, Pal, Cop, Jar, and Aem, is proved to be inhibited by Bae treatment (Cho et al., [@B18]). Secondly, Rhe can suppress MRP\'s activation which may lead the increasing uptake of Aem, Bai, and Bae (Shia et al., [@B102]). Last but not least, Ber can as well decrease BCRP activation, which is capable of promoting the intracellular concentrations of Bai, Emo, and Rhe (Tan et al., [@B109]).

![**The effect of SHXXT constituents on ITs**. Ber, berberine; Cop, coptisine; Pal, palmatine; Jat, jatrorrhizine; Bai, baicalin; Bae, baicalein; Emo, emodin; Aem, aloe-emodin; Rhe, rhein.](fphar-07-00448-g0002){#F2}

Discussion {#s4}
==========

TCM normally used as prescription so as to recruit active contents from different herbals. Modern mutual reinforcement theory believes pharmacodynamics effect after herbal combination is not simply equal to the summing up of each herbal, but to a certain extent, should be more than that. Under most circumstances, a prescription can bring out more advantages in regards of safety and efficacy aspects than a single herb does (Song et al., [@B105]). Apart from expanding effect on one specific part, the combination of several herbals can also give rise to respective effect on different parts, which in other words, supplement other herbals\' disadvantages or helping other herbals to perform their property in a better way.

Inflammatory signal transduction is quite complex network, and suppression on any intersection can partly contribute to the prevention of inflammation process. SHXXT have been high-lighted based on their widely appearance in inflammation-associated treatment for centuries. Clinically, SHXXT is a preferred drug for "coexistence of cold and heat" (Zhang et al., [@B142]). With the constantly deepen researches, it is widely used in the treatment for anti-pathogens, anti-inflammation, gastric mucosal protection, hemostasis, anti-diabetes and so on (Li and Guo, [@B68]). As depicted in Figure [1](#F1){ref-type="fig"}, target with three colored "cross" is to be influenced by constituents form all three compositions (TLR-4, ERK, JNK, p38, Akt, etc.), which lead a fold increase of the final effect. On the other hand, target with less than three "cross" suggest at least one composition was not valid at this part. For example,

1.  Ber from RC is reported to affect TAK1 and interaction between LPS and TLR-4, while RR and main RS constituents barely mentioned.

2.  Bae from RS and Ber from RC inhibit Tyk2 phosphorylation, while no main RR constituent has similar effect.

3.  Rhe from RR and Ber from RC reduce IRF3 phosphorylation level, while the effect of main constituent of RS isn\'t that clear, etc.

The connotative meaning of synergism at pharmacodynamics level is to enhance the effect on a certain target, as well as to expand target-affecting scope, just like what SHXXT constituents have performed. As for the pharmacokinetic level, shown in Figure [2](#F2){ref-type="fig"}, Ber form RS, Rhe form RR and Bae form RC is capable of improving the uptake or reducing the efflux of constituents from the other composition, which ultimately reaches the goal of synergistically influence inflammatory processes and eventually make this formula\'s anti-inflammatory action stronger and wider.

Nowadays, elevated attention has been paid to dose-effect relationship. There is a complicated process which can be expressed as "theory-methodology-formulation-medication-dosage" in TCM clinical therapeutics, showing how important for a formula prescription to have a specific herbal dosage (Zha et al., [@B135]). Basically for western medicine, these is a positive correlation between dose and toxicity. However, TCM at a large dosage tends to have good therapy efficacy with slight side effect (Wang et al., [@B114]). The dosage of Chinese herbals in clinical cases or experimental studies is usually at a relatively higher level than that documented in ancient TCM records (Peng, [@B91]; Sun, [@B107]). RR as an example, the dosage to treat cholestasis in clinical is more than four times the regular dose recommended in the Chinese pharmacopeia (Zhang et al., [@B136]). For now, the widespread explanation is that drug should be administrated to the patient with the correct disorder indications, otherwise it will produce dosage variety and individual detrimental effect (Zhao et al., [@B146]). As displayed in Table [5](#T5){ref-type="table"}, dosage of constituents from SHXXT has a big range with no obvious rule to follow, it is possibly due to different tested animals or cells may have different drug sensitivities, but still need further clarification.

###### 

**The dose range of SHXXT constituent used *in-vivo* and *in-vitro***.

  **Constituent**   **Model**   **Dose lower limit**                **Dose upper limit**
  ----------------- ----------- ----------------------------------- -----------------------------------
  Ber               Cells       0.1 μM Lou et al., [@B77]           90μM Jiang et al., [@B47]
                    Mice        3 mg/kg Domitrović et al., [@B25]   50mg/kg Li et al., [@B60]
                    Rats        50 mg/kg Li et al., [@B61]          200 mg/kg Muto et al., [@B86]
  Bai               Cells       1 μM Ma et al., [@B81]              100 μM Dong et al., [@B26]
                    Mice        100 mg/kg Feng et al., [@B29]       375 mg/kg Wan et al., [@B112]
                    Rats        10 mg/kg Lim et al., [@B69]         25 mg/kg Feng et al., [@B28]
  Bae               Cells       10 μM Fan et al., [@B27]            80 μM Qi et al., [@B93]
                    Mice        25 mg/kg Sahu et al., [@B94]        100 mg/kg Wang W. et al., [@B118]
                    Rats        10 mg/kg Lee et al., [@B56]         40 mg/kg Mao et al., [@B82]
  Emo               Cells       1 μM Lu et al., [@B79]              182.5 μM Meng et al., [@B83]
                    Mice        1 mg/kg Li D. et al., [@B59]        100 mg/kg Xiao et al., [@B125]
                    Rats        10 mg/kg Li A. et al., [@B58]       30 mg/kg Wu et al., [@B124]
  Alo               Cells       5 μM Hu et al., [@B37]              20 μM Hu et al., [@B37]
                    Mice        Not reported                        Not reported
                    Rats        Not reported                        Not reported
  Rhe               Cells       10 μM Domagala et al., [@B24]       200 μM Fernand et al., [@B30]
                    Mice        20 mg/kg Yu et al., [@B131]         80 mg/kg Yu et al., [@B131]
                    Rats        100 mg/kg Ji et al., [@B46]         400 mg/kg Hou et al., [@B36]

Conclusions {#s5}
===========

It is easy to find out not all the SHXXT constituents receive deep-enough investigation on their anti-inflammatory effect, the interaction between main SHXXT constituents and targets outside the nucleus get most focus. Besides, any drug elevating the absorption of Rhe, Ber, and Bae can be employed to promote oral bioavailability of SHXXT. Even though evidence shows P-gp, BCRP, and MRP really are inhibited while reports rarely cover the effect of SHXXT constituents on OCTs or SGLT. Hence, further investigation at these two levels is required to fully explain the mutual reinforcement relationship of RR, RC, and RS.
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ADM

:   adriamycin amycin

Akt

:   Protein kinase B; extracellular signal-regulated kinase

AMPK

:   5′ AMP-activated protein kinase

Ang II

:   angiotensin II

AP-1

:   activator protein 1

ATF

:   Activating transcription factor

BCRP

:   breast cancer resistance protein

CaMK

:   Calcium/calmodulin- dependent kinase

CHOP

:   C/EBP homologous protein 10

CK

:   ginsenoside metabolite compound K

CMC-Na

:   caboxy methyl cellulose

CREB

:   cAMP response element-binding protein

Dex

:   Dexamethasone

Dox

:   Doxorubicin

DSS

:   dextran sulfate sodium

ERK

:   extracellular signal-regulated kinase

GSK3β

:   Glycogen synthase kinase 3 beta

HCM

:   hypercholesterolemic

HG

:   high glucose

HO-1

:   HMOX1heme oxygenase (decycling) 1

I/R

:   ischemia/reperfusion

IKK

:   IκBα kinase

IκBα

:   inhibitor of nuclear factor κBα

iNOS

:   inducible nitric oxide synthase

IRAK

:   Interleukin-1 receptor-associated kinase

IRF3

:   Interferon regulatory factor 3

IRS-1

:   Insulin receptor substrate 1

JAK

:   junas kinase

JNK

:   c-Jun NH2-terminal kinase

LKB1

:   liver kinase B1

LPS

:   lipopolysaccharide

MAPK

:   mitogen-activated protein kinase

MAPKAPK2

:   MAP kinase-activated protein kinase 2

MEK

:   Mitogen-activated protein kinase kinase

MRP

:   multidrug resistance associated protein

mTOR

:   mammalian target of rapamycin 2

MyD88

:   Myeloid differentiation primary response gene 88

NIK

:   NF-κB inducing kinase

Nrf2

:   Nuclear factor (erythroid-derived 2)-like 2

OCT

:   organic cation transporter

OGD

:   oxygen--glucose deprivation

PDTC

:   Pyrrolidine dithiocarbamate

P-gp

:   P-glycoprotein

PI3K

:   phosphoinositide 3-kinase

PMA

:   Phorbol-12-myristate-13-acetate

Poly(I:C)

:   Polyinosinic:polycytidylic acid

PPAR-γ

:   peroxisome proliferator-activated receptor γ

Raf

:   RAF proto-oncogene serine/threonine-protein kinase

SAP

:   severe acute pancreatitis

SGLT1

:   Na+-dependent glucose transporter

SO

:   sham operation

SS

:   sodium salicylate

ST

:   sodium taurocholate

STAT

:   signal transducer and activator of transcription

TAK1

:   transforming growth factor-b-activated kinase

TLR-4

:   toll-like receptor

TNBS, 2, 4

:   6-trinitrobenzene sulfonic acid

TNFR1

:   tumor necrosis factor receptor 1

TRADD

:   Tumor necrosis factor receptor type 1-associated death domain protein

TRAF

:   TNF receptor associated factors

TRM

:   epilepsy-like tremor

Tyk2

:   Non-receptor tyrosine-protein kinase 2

VSMC

:   vascular smooth muscle cell

WKY

:   Wistar-Kyoto

WT

:   wild type.
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